FGFR2/FGFR4 dual targeting antibody-drug conjugate (Novartis/MorphoSys)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameFGFR2/FGFR4 dual targeting antibody-drug conjugate (Novartis/MorphoSys)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate
Mechanisms of ActionFibroblast growth factor 4 modulatorsTubulin inhibitorsFibroblast growth factor 2 modulators
TargetsFibroblast growth factor 4TubulinFibroblast growth factor 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Institutes For Biomedical Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Institutes For Biomedical Research IncMorphosys Ag
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A